勃林格殷格翰将II期抗炎药加入其呼吸道疾病产品线

Pharmadeals Review Pub Date : 2012-07-31 DOI:10.3833/PDR.V2012I7.1786

Heather Cartwright

{"title":"勃林格殷格翰将II期抗炎药加入其呼吸道疾病产品线","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I7.1786","DOIUrl":null,"url":null,"abstract":"Boehringer Ingelheim has acquired global rights to Funxional Therapeutics’ Phase II oral anti-inflammatory drug FX125L, a potential first-in-class somatotaxin, as well as a somatotaxin development programme. The deal will strengthen Boehringer Ingelheim’s respiratory pipeline, which includes the long-acting beta agonist olodaterol and nintedanib for idiopathic pulmonary fibrosis. The company already markets the blockbuster COPD therapy Spiriva® (tiotropium bromide).","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"28 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Boehringer Ingelheim Adds Phase II Anti-Inflammatory Drug to its Respiratory Disease Pipeline\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I7.1786\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Boehringer Ingelheim has acquired global rights to Funxional Therapeutics’ Phase II oral anti-inflammatory drug FX125L, a potential first-in-class somatotaxin, as well as a somatotaxin development programme. The deal will strengthen Boehringer Ingelheim’s respiratory pipeline, which includes the long-acting beta agonist olodaterol and nintedanib for idiopathic pulmonary fibrosis. The company already markets the blockbuster COPD therapy Spiriva® (tiotropium bromide).\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"28 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I7.1786\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I7.1786","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

勃林格殷格翰(Boehringer Ingelheim)已获得功能性治疗公司(功能性治疗公司)的II期口服抗炎药FX125L的全球权利，FX125L是一种潜在的一流生长抑素，以及一种生长抑素开发项目。该交易将加强勃林格殷格翰的呼吸管道，其中包括用于特发性肺纤维化的长效β受体激动剂olodaterol和尼达尼布。该公司已经销售重磅COPD治疗药物Spiriva®(噻托溴铵)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Boehringer Ingelheim Adds Phase II Anti-Inflammatory Drug to its Respiratory Disease Pipeline

Boehringer Ingelheim has acquired global rights to Funxional Therapeutics’ Phase II oral anti-inflammatory drug FX125L, a potential first-in-class somatotaxin, as well as a somatotaxin development programme. The deal will strengthen Boehringer Ingelheim’s respiratory pipeline, which includes the long-acting beta agonist olodaterol and nintedanib for idiopathic pulmonary fibrosis. The company already markets the blockbuster COPD therapy Spiriva® (tiotropium bromide).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量